Perspective on fibrinolytic therapy in COVID-19: the potential of inhalation therapy against suppressed-fibrinolytic-type DIC

A high rate of thrombotic complications, such as pulmonary embolism, has been linked to mortality in COVID-19, and appropriate treatment of thrombosis is important for lifesaving. Although heparin is frequently used to treat thrombotic pathology in COVID-19, pulmonary embolism is still seen in sever...

Descripción completa

Detalles Bibliográficos
Autores principales: Asakura, Hidesaku, Ogawa, Haruhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499019/
https://www.ncbi.nlm.nih.gov/pubmed/32959003
http://dx.doi.org/10.1186/s40560-020-00491-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499019/
https://www.ncbi.nlm.nih.gov/pubmed/32959003
http://dx.doi.org/10.1186/s40560-020-00491-y

Ejemplares similares